FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
Targeted Oncology23h
FDA Accepts sBLA for Nivolumab/Ipilimumab Combo in dMMR/MSI-H CRC
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
Merck’s application for keytruda in HNSCC granted priority review by FDA
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
2BMY : Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...
Le Lézard3h
Simplilearn Strengthens Leadership with the Appointment of Shane Clem as VP of Strategic Partnerships
Simplilearn, a global leader in digital upskilling, is excited to announce the appointment of Shane Clem as Vice President of ...
Le Lézard2h
NeoVolta (NEOV) $300M Loan Application Passes Phase 2 of Department of Energy Loan Program
NeoVolta Inc. ("NeoVolta"), a leading innovator in energy storage solutions, announced today that it has completed phase two of its loan application for $300M from the U.S. Department of Energy (DOE) ...
Global Vaccine Contract Manufacturing Market To Boost With A Significant ~7% CAGR By 2032 | Delveinsight
The vaccine contract manufacturing market is expanding rapidly, driven by rising global demand for immunization and a growing emphasis on preventive ...
precisionmedicineonline21h
BMS Seeking FDA Approval for Opdivo-Yervoy in Frontline MSI-High, dMMR Advanced Colorectal Cancer
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.